Strategy: Cardiovascular disease is the leading cause of death, and Heart Failure with reduced Left Ventricular Ejection Fraction (LVEF) is the major one. We believe transplanting sufficient number of ventricular cardiomyocytes is the best possible approach to cure Heart Failure with Reduced Ejection Fraction (HFrEF).
Target indication: Target indication is HFrEF, including Dilated Cardiomyopathy (DCM), Old Myocardial Infraction (OMI) and Dilated phase of Hypertrophic Cardiomyopathy (D-HCM)
Product: allogeneic iPSC-derived cardiomyocytes
Route of Administration: Intramyocardial Injection
Development Stage: Pre-Clinical, enter FIH in 2020
Other than our lead pipeline HS-001, intramyocardial injection of allogeneic iPSC-derived cardiomyocytes, researches are ongoing such as using autologous iPSC and HLA knock-out iPSC, which are free of immune rejection. We are also conducting research with a partner to develop more convenient injection methodologies that can be used in wide range of institutions.
Mr. Yasui joined Heartseed in 2019 as COO. Before joining Heartseed, he held various positions with increasing responsibilities at AbbVie /Abbott Japan, including Business Unit Manager, Immunology and Group Manager, Market Access. He also worked at Bain. He graduated from the Univ. of Tokyo, Pharmaceutical Sciences. (MSc)